105 related articles for article (PubMed ID: 35711974)
1. Association between TOP2A, RRM1, HER2, ERCC1 expression and response to chemotherapy in patients with non-muscle invasive bladder cancer.
Liu Z; Xing L; Zhu Y; Shi P; Deng G
Heliyon; 2022 Jun; 8(6):e09643. PubMed ID: 35711974
[TBL] [Abstract][Full Text] [Related]
2. Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, β-tubulin III, thymidylate synthetase, and topoisomerase IIα in breast cancer: Association with clinicopathological characteristics.
Li J; Sun P; Huang T; He S; Li L; Xue G
Medicine (Baltimore); 2021 Apr; 100(14):e25344. PubMed ID: 33832110
[TBL] [Abstract][Full Text] [Related]
3. Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: A hierarchical clustering analysis.
Yu Y; Ding S; Liang Y; Zheng Y; Li W; Yang L; Zheng X; Jiang J
Exp Ther Med; 2014 Jun; 7(6):1578-1582. PubMed ID: 24926347
[TBL] [Abstract][Full Text] [Related]
4. Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiation.
Shilkrut M; Wu A; Thomas DG; Hamstra DA
Mol Clin Oncol; 2014 May; 2(3):479-487. PubMed ID: 24772321
[TBL] [Abstract][Full Text] [Related]
5. Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.
Simon GR; Schell MJ; Begum M; Kim J; Chiappori A; Haura E; Antonia S; Bepler G
Cancer; 2012 May; 118(9):2525-31. PubMed ID: 22028294
[TBL] [Abstract][Full Text] [Related]
6. [Expression and predictive role of excision repair cross complementation group 1, ribonucleotide reductase subunit M1, and β-tubulin 3 in postoperative patients with non-small cell lung cancer receiving adjuvant chemotherapy].
Shi Y; Chen L; Li J; Lü YL; Jiao SC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2010 Aug; 32(4):375-82. PubMed ID: 20868593
[TBL] [Abstract][Full Text] [Related]
7. The prognostic value of ERCC1 and RRM1 gene expression in completely resected non-small cell lung cancer: tumor recurrence and overall survival.
Tantraworasin A; Saeteng S; Lertprasertsuke N; Arayawudhikul N; Kasemsarn C; Patumanond J
Cancer Manag Res; 2013; 5():327-36. PubMed ID: 24124391
[TBL] [Abstract][Full Text] [Related]
8. Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer.
Xu CW; Wang G; Wang WL; Gao WB; Han CJ; Gao JS; Li Y; Wang L; Zhang LY; Zhang YP; Tian YW; Fang JN
Exp Ther Med; 2015 Mar; 9(3):880-884. PubMed ID: 25667646
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of ERCC1, RRM1 and BRCA1 in surgically-treated patients with non-small cell lung cancer.
Pesta M; Kulda V; Fiala O; Safranek J; Topolcan O; Krakorova G; Cerny R; Pesek M
Anticancer Res; 2012 Nov; 32(11):5003-10. PubMed ID: 23155271
[TBL] [Abstract][Full Text] [Related]
10. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
[TBL] [Abstract][Full Text] [Related]
11. ERCC1 and RRM1 as a predictive parameter for non-small cell lung, ovarian or pancreas cancer treated with cisplatin and/or gemcitabine.
Ulker M; Duman BB; Sahin B; Gumurdulu D
Contemp Oncol (Pozn); 2015; 19(3):207-13. PubMed ID: 26557761
[TBL] [Abstract][Full Text] [Related]
12. Individualized chemotherapy guided by the expression of
Li J; Sun P; Huang T; He S; Li L; Xue G
Oncol Lett; 2021 Jan; 21(1):21. PubMed ID: 33240427
[No Abstract] [Full Text] [Related]
13. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy.
Zhao H; Zhang H; Du Y; Gu X
Tumour Biol; 2014 Dec; 35(12):12679-88. PubMed ID: 25227663
[TBL] [Abstract][Full Text] [Related]
14. Expression patterns and prognostic significances of
Khetan K; Sahoo RK; Baloda V; Shalimar ; Vishnubhatla S; Saraya A; Dash NR; Sharma A; DattaGupta S; Das P
Indian J Pathol Microbiol; 2021 Jun; 64(Supplement):S160-S165. PubMed ID: 34135160
[TBL] [Abstract][Full Text] [Related]
15. ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer.
Su C; Zhou S; Zhang L; Ren S; Xu J; Zhang J; Lv M; Zhang J; Zhou C
Med Oncol; 2011 Dec; 28(4):1411-7. PubMed ID: 20467918
[TBL] [Abstract][Full Text] [Related]
16. Response to gemcitabine-platinum chemotherapy by single nucleotide polymorphisms of RRM1 and ERCC1 genes in patients with non-small-cell lung cancer.
Oh IJ; Ban HJ; Kim KS; Song SY; Na KJ; Kim YH; Ahn SJ; Choi S; Cho HJ; Kim YC
Thorac Cancer; 2012 Feb; 3(1):19-26. PubMed ID: 28920258
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of the mRNA expression of
Sun S; Shi W; Wu Z; Zhang G; Yang BO; Jiao S
Exp Ther Med; 2015 Sep; 10(3):937-941. PubMed ID: 26622418
[TBL] [Abstract][Full Text] [Related]
18. [Expression of RRM1 and ERCC1 genes in tumor tissues and peripheral blood lymphocytes of advanced non-small cell lung cancer].
Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Shen-Tu JZ
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2012 Sep; 41(5):540-6. PubMed ID: 23086647
[TBL] [Abstract][Full Text] [Related]
19. Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival.
Zito Marino F; Baselice S; Erra S; Ronchi A; Montella M; Morgillo F; Vicidomini G; Santini M; Poziello G; Cozzolino I; Accardo M; Franco R
Appl Immunohistochem Mol Morphol; 2021 Mar; 29(3):231-238. PubMed ID: 32842027
[TBL] [Abstract][Full Text] [Related]
20. RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
Xu YC; Zhang FC; Li JJ; Dai JQ; Liu Q; Tang L; Ma Y; Xu Q; Lin XL; Fan HB; Wang HX
Oncol Rep; 2015 Oct; 34(4):1883-94. PubMed ID: 26252353
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
